{
    "clinical_study": {
        "@rank": "102692", 
        "acronym": "KBASE", 
        "arm_group": [
            {
                "arm_group_label": "Young normal controls", 
                "description": "age : 20 ~ 55\nwithout dementia, MCI, or other major neurological/psychiatric illness"
            }, 
            {
                "arm_group_label": "Elderly normal controls", 
                "description": "age : 55 ~ 90\nwithout dementia, MCI, or other major neurological/psychiatric illness"
            }, 
            {
                "arm_group_label": "MCI (Mild cognitive impairment)", 
                "description": "age : 55 ~ 90\nwithout major neurological/psychiatric illness\nconcern regarding a change in cognition, lower performance in episodic memory domains that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
            }, 
            {
                "arm_group_label": "AD (Alzheimer's diseases)", 
                "description": "age: 55 ~ 90\nNational Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia"
            }
        ], 
        "biospec_descr": {
            "textblock": "Plasma, Serum, DNA, RNA"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a prospective cohort study for cognitively normal (young and old), mild cognitive\n      impairment, and Alzheimer's disease people"
        }, 
        "brief_title": "Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease", 
        "completion_date": {
            "#text": "February 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Alzheimer's Disease", 
            "Mild Cognitive Impairment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Cognition Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aim of the study is\n\n        -  To search new biomarkers and develop clinically applicable early diagnosis and\n           prediction methods of Alzheimer's disease.\n\n        -  To investigate contributing factors to AD-related early brain changes through annual\n           comprehensive clinical and neuropsychological evaluation and biannual brain imaging\n           (MRI, Fluorodeoxyglucose(FDG)-PET, and Pittsburgh compound B (PiB)-PET) with blood\n           sampling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Participants will be classified as either Alzheimer's disease(AD) group, mild cognitive\n        impairment(MCI) group, elderly normal controls or young normal controls. Specific\n        inclusion criteria for each group is described below.\n\n        [Inclusion criteria: AD]\n\n          -  Age : 55 - 90\n\n          -  Clinical Dementia Rating (CDR)=0.5 or 1\n\n          -  Diagnostic and Statistical Manual-IV(DSM-IV) criteria for dementia\n\n          -  National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD\n             dementia\n\n          -  Study partner or caregiver to accompany patient to all scheduled visits\n\n          -  Written informed consent\n\n        [Inclusion criteria: MCI (amnestic)]\n\n          -  Age : 55 - 90\n\n          -  Clinical Dementia Rating (CDR)=0.5\n\n          -  Concern regarding a change in cognition (obtained from the subject, from an informant\n             who knows the subject, or from a skilled clinician observing the subject)\n\n          -  Lower performance in episodic memory domains that is greater than would be expected\n             for the subject's age and educational background\n\n          -  Preservation of independence in functional abilities\n\n          -  Study partner or caregiver to accompany subject to all scheduled visits\n\n          -  Written informed consent\n\n        [Inclusion criteria: Elderly normal controls]\n\n          -  Age : 55 - 90\n\n          -  Clinical Dementia Rating (CDR)=0\n\n          -  Those with contactable Informant\n\n          -  Written informed consent\n\n        [Inclusion criteria: Young normal controls]\n\n          -  Age : 20 - 55\n\n          -  Clinical Dementia Rating (CDR)=0\n\n          -  Written informed consent\n\n        [Exclusion criteria: general]\n\n          -  Past history or presence of major psychiatric illness (e.g. schizophrenia, bipolar\n             disorder, alcohol/substance abuse or dependence, delirium)\n\n          -  Significant neurologic or medical condition that can influence the mental state\n\n          -  Contraindications for MRI scan (e.g. pacemaker, claustrophobia)\n\n          -  Illiteracy\n\n          -  Significant visual or hearing difficulty\n\n          -  Taking investigational drug\n\n          -  In pregnancy or breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "90 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Young and elderly normal controls: community-based population AD and MCI: clinic or\n        community-based population"
            }
        }, 
        "enrollment": {
            "#text": "920", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137460", 
            "org_study_id": "KBASE01", 
            "secondary_id": [
                "NRF-2013M3C7A1072998", 
                "NRF-2013M3C7A1069644"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alzheimer's disease", 
            "Early diagnosis", 
            "Prediction", 
            "Biomarker", 
            "Imaging"
        ], 
        "lastchanged_date": "May 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University College of Medicine"
            }, 
            "investigator": {
                "last_name": "Dong Young Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "4", 
        "official_title": "Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease", 
        "overall_contact": {
            "email": "selfpsy@snu.ac.kr", 
            "last_name": "Dong young Lee, MD, PhD", 
            "phone": "+82-2-2072-2205"
        }, 
        "overall_official": {
            "affiliation": "Department of Psychiatry, Seoul National University College of Medicine", 
            "last_name": "Dong Young Lee, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Group difference in baseline brain amyloid deposition and the relationship between the amount of brain amyloid deposition and clinical, neuropsychological, neuroimaging, genetic, biochemical measurement will be investigated.", 
            "measure": "The amount of brain amyloid deposition", 
            "safety_issue": "No", 
            "time_frame": "baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137460"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Dong Young Lee", 
            "investigator_title": "professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Group difference for each clinical, neuropsychological, structural and functional neuroimaging, genetic, biochemical measurement and correlations among these variables will be investigated.", 
                "measure": "Group difference for each clinical, neuropsychological, structural and functional neuroimaging, genetic, biochemical measurement", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "The change of brain amyloid deposition and its relation to the clinical, neuropsychological, neuroimaging, genetic and biochemical measurement will be assessed.", 
                "measure": "Change of brain amyloid deposition", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2yr, 4yr"
            }, 
            {
                "description": "The change of clinical, neuropsychological measurement and the relationship between these variables and other biomarkers will be assessed.", 
                "measure": "Change of clinical, neuropsychological measurement", 
                "safety_issue": "No", 
                "time_frame": "baseline, 1yr, 2yr,3yr, 4yr"
            }, 
            {
                "description": "The change of structural and functional MRI measures and glucose metabolism of the brain the relationship between these variables and other  clinical, neuropsychological, neuroimaging, biochemical, genetic biomarkers will be assessed.", 
                "measure": "Change of structural and functional neuroimaging measurement", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2yr, 4yr"
            }, 
            {
                "description": "The change of blood-based biochemical measurement and the relationship between these variables and other clinical, neuropsychological, neuroimaging, biochemical, genetic biomarkers will be assessed.", 
                "measure": "Change of biochemical measurement", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2yr, 4yr"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ministry of Science, ICT, and Future Planning, Republic of Korea", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Seoul National University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Dong Young Lee", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}